Stereotactic body radiotherapy for localized prostate cancer - 5-year efficacy results.

ABSTRACT:

Background

The use of stereotactic body radiotherapy (SBRT) as the primary treatment modality in clinically localized prostate cancer (PCa) is emerging. The aim of the study was to analyze the long-term results of PCa patients treated with SBRT.

Methods

This non-selected, real-life patient cohort included 213 patients with localized PCa treated with a robotic SBRT device during 2012-2015.

Results

The median follow-up was 64 months (range, 10-85 months), and all risk-groups were represented as 47 (22.1%), 56 (26.3%) and 110 (51.6%) patients were classified into D'Amico risk stratification of low, intermediate and high-risk groups, respectively. Androgen deprivation therapy (ADT) was administered to 64.3% of the patients. At cut-off, the biochemical relapse-free surviva

SUBMITTER: Vuolukka K 

PROVIDER: S-EPMC7362647 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature